PD-1 Blockade for HIV Eradication? PDF Print E-mail
Written by Robert Friedman   
Monday, 02 January 2012 16:08

Targeting the PD-1 Pathway for HIV Eradication?

antibodies

The blockade of PD-1/PD-L1 interaction represents a promising therapeutic strategy for reactivation of virus-specific effector T cells to exert pathogen eradication in chronic viral infections like HIV. The first clinical trials are waiting the green light to start.

Programmed Death-1 (PD-1) is a negative regulator of T cell activation and proliferation that mediates suppressive action by binding to its ligands PD-L1 and PD-L2.


T cell exhaustion is a state of T cell dysfunction that arises during many chronic infections and cancer.


Over the last few years, it has been established that PD-1 plays an active and reversible role in T cell exhaustion.


Under physiological conditions, PD-1 is induced after T cell activation and serves as an inhibitory feedback to dampen the TCR signalling cascade and prevent excessive T cell activation. PD-1 plays also an important role in the tolerance to self antigens.

 

PD-1-Role


Expression of PD-1 ligands is elevated in HIV infection in an effort to reduce ongoing inflammation.


HIV can also directly up-regulate the expression of PD-1 ligands on antigen presenting cells leading to an impairment of these cells’ function and, as a consequence, of HIV specific immune responses.


Increased PD-1 expression has also been correlated with worse immune reconstitution during ART.


PD-1, on the other hand, may also contribute to the maintenance of latent HIV in memory CD4 T cells.

PD-1 expressing memory CD4 cells contain more proviral DNA than PD-1 low cells, and PD-1 blockade triggers HIV expression in CD4 cells in vitro.


Immunotherapy based on the blockade of PD-1/PD-L1 interaction represents a promising therapeutic strategy for reactivation of virus-specific effector T cells to exert pathogen eradication in chronic HIV infection and also further purge the remaining viral reservoir.


The first clinical trial using anti PD-1 antibodies is under approval and ready to start.


This trial will have to answer a couple of questions:

-Is PD-1 blockade safe in HIV-infected patients?

-Does PD-1 blockade enhance HIV specific immune responses?

-Does PD-1 blockade allows a better immune reconstitution than what is obtained with ART alone?

-Does PD-1 blockade decreases residual inflammation found in HIV infection?

-Does PD-1 blockade reduces the level of HIV reservoirs


References

-Porichis F et al. Role of PD-1 in HIV Pathogenesis and as Target for Therapy. Curr HIV/AIDS Rep 2011; Dec 24. [Epub ahead of print]

-Eichbaum Q. PD-1 signaling in HIV and chronic viral infection potential for therapeutic intervention? Curr Med Chem. 2011; 18(26):3971-80.

- Grabmeier-Pfistershammer K et al. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J Acquir Immune Defic Syndr. 2011;56(2):118-24.



Key words: PD-1 HIV, PD-1 antibodies HIV
 

Gravatar
julie fox 20.02.2012 (19:30:33)  
who is leading this study Yes No  

who is leading this study
http://www.hiv-reservoir.net/index.php/the-news/202-pd-1-blockade-for-hiv-eradication.html

 
   
       
Gravatar
Alain Lafeuillade 20.02.2012 (19:42:11)  
ACTG anti-PD-1 trial Yes No  

Hiroyu Hatano at San Francisco General Hospital

 
   
       

Smileys

:confused: :cool: :cry: :laugh: :lol: :normal: :blush: :rolleyes: :sad: :shocked: :sick: :sleeping: :smile: :surprised: :tongue: :unsure: :whistle: :wink: 

  1000 Characters left

Antispam Refresh image Case sensitive